Stocks / NASDAQ / Edge Therapeutics, Inc.

Edge Therapeutics, Inc.

Our Opinion

Edge Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.

Supporting Evidence:

NimoGel™ Shows Promise at Preventing Delayed Complications of Sudden Brain Injury in a Preclinical Study Presented at the International Stroke Conference

“This preclinical study suggests that it is possible to achieve adequate and sustained concentrations of nimodipine locally and prevent cerebral vasospasm and other potentially deadly complications after brain injury. Based on these encouraging results in a large animal model, further evaluation of NimoGel in human clinical trials is warranted,” said R. Loch Macdonald, MD, PhD, Keenan Endowed Chair and Head of the Division of Neurosurgery at St. Michael’s Hospital, University of Toronto and Chief Scientific Officer of Edge Therapeutics.

Company Description

Edge Therapeutics, Inc. operates as biotechnology company which develops therapies. engages in the discovery, development, and commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions for which limited or no current therapies exist. It develops the Precisa Platform of EG-1962 and the EG-1964 treatments. The company was founded on January 22, 2009 by Brian A. Leuthner, Robert Loch Macdonald and Carl J. Soranno and is headquartered in Berkeley Heights, NJ. [Source: MarketWatch]

Company Website: